Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirasemtiv open-label extension in ALS after VITALITY-ALS
NL-OMON45447Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tirasemtiv in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Cytokinetics. Primary endpoint: Long-term safety and tolerability of tirasemtiv. Started Jul 2017; status: active, not recruiting.
02
Drugs
tirasemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON45447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45447.